UFC 174 main event fighter Ali Bagautinov has been suspended for a year following a failed post-fight drug test. Bagautinov was defeated by UFC flyweight champion Demetrious Johnson at the June 14 event.
The British Columbia Athletic Commission released the results of the test to MMAjunkie.com, which showed Bagutinov (13-3) with erythropoietin in his system. He was one of eight fighters on the Canadian card to be tested along with Johnson and six others.
“Results received by this office from the June 2 tests on Mr. Bagautinov were positive for erythropoietin, or EPO – a substance banned by the World Anti-Doping Agency,” BCAC Commissioner Dave Maedel said. “These results were not available prior to the UFC 174 event due to lab processing times. Mr. Bagautinov lost his bid for the flyweight title to Demetrious Johnson. I have suspended Mr. Bagautinov’s licence to compete in British Columbia for a period of one year.”
EPO controls the production of red blood cells and is considered a performance-enhancer in the world of sports. Lance Armstrong was found to have used the drug during his run to several Tour de France cycling titles.
Following news of the test results, the UFC released a statement, saying, “UFC 174 competitor Ali Bagautinov has been suspended by the British Columbia Athletic Commission for testing positive for erythropoietin (EPO). He was also informed that his positive test violated the UFC Fighter Conduct Policy and Promotional Agreement with Zuffa, LLC.
“The UFC has a strict, consistent policy against the use of any illegal and/or performance-enhancing drugs, stimulants or masking agents by our athletes. Bagautinov will serve a one-year suspension and must pass a drug test at the conclusion of his suspension before receiving clearance to compete in the UFC again.”